[关键词]
[摘要]
目的 研究复方倍他米松注射液联合塞来昔布胶囊治疗膝关节骨性关节炎的临床疗效。方法 选取2017年6月—2018年6月酉阳土家族苗族自治县人民医院收治的100例膝关节骨性关节炎患者作为研究对象,采用随机数字表法将患者分为对照组和治疗组,每组各50例。对照组患者口服塞来昔布胶囊,200 mg/次,1次/d;治疗组在对照组的基础上关节腔内注射复方倍他米松注射液,1 mL/次,1次/周。两组患者均治疗4周。观察两组患者的临床疗效,同时比较两组治疗前后的膝关节高频超声参数、骨关节炎指数可视化量表(WOMAC)评分、视觉模拟评分法(VAS)评分和血清炎性因子水平。结果 治疗后,对照组和治疗组的总有效率分别为84.00%、96.00%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者软骨厚度明显增加(P<0.05);且治疗后治疗组软骨厚度明显高于对照组(P<0.05)。治疗后,两组患者WOMAC评分显著升高,VAS评分显著降低(P<0.05);且治疗后治疗组WOMAC和VAS评分显著优于对照组(P<0.05)。治疗后,两组患者基质金属蛋白酶-3(MMP-3)、白细胞介素-1β(IL-1β)、PG蛋白聚糖(PG)、软骨寡聚基质蛋白(COMP)水平均显著降低(P<0.05);且治疗后治疗组血清炎性因子水平显著低于对照组(P<0.05)。结论 复方倍他米松注射液联合塞来昔布胶囊治疗膝关节骨性关节炎具有较好的临床疗效,能够改善患者的临床症状,降低炎性因子水平,安全性较高,具有一定的临床推广应用价值。
[Key word]
[Abstract]
Objective To study the clinical efficacy of Compound Betamethasone Injection combined with Celecoxib Capsules in treatment of knee osteoarthritis. Methods Patients (100 cases) with knee osteoarthritis in People's Hospital of Youyang Tujia and Miao Autonomous County from June 2017 to June 2018 were divided into control and treatment groups by random number table method, and each group had 50 cases. Patients in the control group were po administered with Celecoxib Capsules, 200 mg/time, once daily. Patients in the treatment group were intra articular injection administered with Compound Betamethasone Injection on the basis of control group, 1 mL/time, once weekly. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy were evaluated, and high frequency ultrasonic parameters of knee joint, WOMAC score, VAS score, and serum inflammatory factor levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 84.00% and 96.00%, respectively, and there were differences between two groups (P<0.05). After treatment, the cartilage thickness in two groups were significantly increased (P<0.05). And the cartilage thickness in the treatment group was significantly higher than that in the control group (P<0.05). After treatment, the WOMAC scores in two groups were significantly increased, but the VAS score were decreased (P<0.05). And the WOMAC and VAS scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, MMP-3, IL-1β, PG, and COMP levels in two groups were significantly decreased (P<0.05). And serum inflammatory factor levels in the treatment group were significantly lower than those in the control group (P<0.05).Conclusion Compound Betamethasone Injection combined with Celecoxib Capsules has good clinical efficacy in treatment of knee osteoarthritis, can improve clinical symptoms, and reduce the inflammatory factors level, with high safety, which has a certain clinical application value.
[中图分类号]
[基金项目]